Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Posdinemab in Healthy Japanese Subjects
NCT03689153Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of posidinemab in Alzheimer's disease (AD) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events at 23 weeks. Started Sep 2018; status: completed.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03689153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689153.